| Literature DB >> 36206460 |
Phil A Hart1, Georgios I Papachristou1, Walter G Park2, Anne-Marie Dyer3, Vernon M Chinchilli3, Elham Afghani4, Venkata S Akshintala4, Dana K Andersen5, James L Buxbaum6, Darwin L Conwell1, Kathleen M Dungan7, Jeffrey J Easler8, Evan L Fogel8, Carla J Greenbaum9, Rita R Kalyani10, Murray Korc11, Richard Kozarek, Maren R Laughlin12, Peter J Lee1, Jennifer L Maranki13, Stephen J Pandol14, Anna Evans Phillips15, Jose Serrano5, Vikesh K Singh4, Cate Speake9, Temel Tirkes16, Frederico G S Toledo17, Guru Trikudanathan18, Santhi Swaroop Vege19, Ming Wang3, Cemal Yazici20, Atif Zaheer21, Christopher E Forsmark22, Melena D Bellin, Dhiraj Yadav15.
Abstract
ABSTRACT: Acute pancreatitis (AP) is a disease characterized by an acute inflammatory phase followed by a convalescent phase. Diabetes mellitus (DM) was historically felt to be a transient phenomenon related to acute inflammation; however, it is increasingly recognized as an important late and chronic complication. There are several challenges that have prevented precisely determining the incidence rate of DM after AP and understanding the underlying mechanisms. The DREAM (Diabetes RElated to Acute Pancreatitis and its Mechanisms) Study is a prospective cohort study designed to address these and other knowledge gaps to provide the evidence needed to screen for, prevent, and treat DM after AP. In the following article, we summarize literature regarding the epidemiology of DM after AP and provide the rationale and an overview of the DREAM study.Entities:
Mesh:
Year: 2022 PMID: 36206460 PMCID: PMC9555871 DOI: 10.1097/MPA.0000000000002079
Source DB: PubMed Journal: Pancreas ISSN: 0885-3177 Impact factor: 3.243